Accessibility Menu
NKGen Biotech logo

NKGen Biotech(OTC) NKGN

Current Price$0.06
Market Cap$7.84MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-99%
5 Year-99%
1 Year-73%
1 Month+0%
NKGen Biotech last closing stock price
MetricPriceDate
Last closeUSD 0.062026-07-23
NKGen Biotech stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.062026-07-16
1 month+0%USD 0.062026-06-23
3 month+0%USD 0.062026-04-24
Year to date+20%USD 0.052025-12-31
1 year-72.73%USD 0.222025-07-23
3 year-99.42%USD 10.422023-07-24
5 year-99.38%USD 9.732021-07-23
Since inception-99.38%USD 9.702021-07-13

NKGen Biotech Financials at a Glance

Market Cap

$7.84MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$652.00K

Net Income (TTM)

-$23.55M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

1.80 (High)

Price

$0.06

Volume

1,467

Open

$0.06

Previous Close

$0.06

Daily Range

$0.06 - $0.06

52-Week Range

$0.00 - $0.33

Estimated Earnings Date

Mar 2, 2026

NKGN News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About NKGen Biotech

NKGen develops cell therapies for people with diseases like Alzheimer’s and cancer. Its treatments aim to help the body’s immune system fight illness. The company’s work targets patients with few existing options.

Cell Science, Simplified: What NKGen Sells

  • SNK01 Therapy: Personalized cell treatment for Alzheimer’s and Parkinson’s disease; in clinical trials; 0% of revenue as of Q4 2024.
  • SNK02 Therapy: Off-the-shelf cell therapy for solid tumors; in clinical trials; 0% of revenue as of Q4 2024.
  • Manufacturing Services: In-house production and preservation of cell therapies; supports clinical pipeline; 100% of reported revenue in Q4 2024.

Growth Spurts and Strategic Moves

  • Formed through a merger with Graf Acquisition Corp. IV in September 2023.
  • Discontinued a clinical partnership with Affimed GmbH in June 2023.
  • Expanded clinical trials for SNK01 and SNK02 in the U.S. and Canada since 2023.
  • Secured multiple financing agreements, including PIPE and convertible notes, in 2023 and 2024.

What Makes NKGen Stand Out

NKGen’s proprietary process enhances natural killer cell activity for targeted therapies. The company controls its own manufacturing, supporting clinical flexibility. Its focus on both neurodegenerative diseases and cancer is unusual for a cell therapy firm.

Five Things You Need to Know

  • Revenue was $652,000 in Q4 2024, up from $0 in Q4 2023.
  • Net loss was $29 million in Q4 2024, improving 12.5% from Q4 2023.
  • Cash and equivalents were $8,000 as of September 30, 2024.
  • Working capital deficit reached $36.2 million as of September 30, 2024.
  • Substantial doubt exists about the company’s ability to continue as a going concern.

Bottom Line

NKGen is an early-stage biotech focused on cell therapies for hard-to-treat diseases. The company faces significant financial challenges as it advances its clinical pipeline.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

26

CEO

Paul Y. Song, MD, PhD

Website

www.nkgenbiotech.com

Headquarters

Santa Ana, CA 92705, US

NKGN Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

150.91%

Return on Capital

N/A

Return on Assets

-184525.00%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$7.84MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

130.60M

Volume

1.47K

Avg. Volume

3.98K

Financials (TTM)

Gross Profit

$326.00K

Operating Income

-$24.01M

EBITDA

$21.54M

Operating Cash Flow

-$19.65M

Capital Expenditure

-$52.00K

Free Cash Flow

-$19.70M

Cash & ST Invst.

$6.00K

Total Debt

$38.19M

NKGen Biotech Performance Analysis

NKGen Biotech annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 0N/A
20222022-12-31USD 77,000N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
NKGen Biotech sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30N/A
Q32024-09-30N/A
Q42024-12-31N/A
Q12025-03-31-100.0%
NKGen Biotech annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -0.05N/A
20222022-12-31USD -4.219010.4%
20232023-12-31USD -5.3827.8%
20242024-12-31USD -1.54-71.4%
NKGen Biotech sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30-168.0%
Q32024-09-30122.4%
Q42024-12-31-613.3%
Q12025-03-3194.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

N/A

Gross Margin

0.00%

N/A

Market Cap

$7.84MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$301.39K

N/A

Employees

26

N/A

Net Income

$15.35M

+385.2%

EBITDA

$16.24M

+507.3%

Quarterly Fundamentals

Name
Q1 2025YOY CHG

Total Cash

$6.00K

-82.4%

Total Debt

$38.19M

+71.9%

Accounts Receivable

$23.00K

-11.5%

Inventory

$0.00

N/A

Long Term Debt

$11.28M

+7.5%

Short Term Debt

$26.91M

+129.6%

Return on Assets

-1845.25%

N/A

Return on Invested Capital

-1123.58%

N/A

Free Cash Flow

-$2.85M

+29.3%

Operating Cash Flow

-$2.80M

+30.6%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MLECMoolec Science S.A.
$7.20+0.21%
ELABPMGC Holdings Inc.
$0.90-5.15%
NCELNewcelX Ltd.
$3.76-1.18%
ATXIAvenue Therapeutics, Inc.
$0.28+6.01%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$92.32-0.08%
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%

Questions About NKGN

What is the current price of NKGen Biotech?

NKGen Biotech is trading at $0.06 per share.

What is the 52-week range for NKGen Biotech?

Over the past 52 weeks, NKGen Biotech has traded between $0.00 and $0.33.

How much debt does NKGen Biotech have?

As of the most recent reporting period, NKGen Biotech reported total debt of $38.19M.

How much cash does NKGen Biotech have on hand?

NKGen Biotech reported $29.00K in cash and cash equivalents in its most recent financial results.

What is NKGen Biotech’s dividend yield?

NKGen Biotech does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services